Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04897009 · ClinicalTrials.gov registry record
Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer
A clinical trial of Invasive Breast Carcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- 38
- Enrollment target
- 1
- Study location
NCT04897009 is a study of Invasive Breast Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 38 participants, below the 484-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04897009, a study of Invasive Breast Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial evaluates the impact of chemotherapy before surgery (neoadjuvant) on the peripheral blood immune phenotype in patients with operable breast cancer. Collecting blood and information from patients with breast cancer may help to understand how the immune system influences response to treatment, and how the immune system reacts to breast cancer treatment.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2028-06-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04897009
The ClinicalTrials.gov registry entry for NCT04897009 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT04897009 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04897009 about?
NCT04897009 is a clinical study titled "Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer". This early phase I trial evaluates the impact of chemotherapy before surgery (neoadjuvant) on the peripheral blood immune phenotype in patients with operable breast cancer. Collecting blood and information from patients with breast cancer may help to understand how the immune system influences respo...
What is the current status of trial NCT04897009?
This trial is currently active not recruiting. The enrollment target is 38 participants. The study started on 2021-06-09. Estimated completion is 2028-06-08.
What conditions does trial NCT04897009 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma.
What interventions are being tested in trial NCT04897009?
The interventions under investigation include: Biospecimen Collection (PROCEDURE).
Who is sponsoring clinical trial NCT04897009?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04897009 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
RECRUITING · Phase 1
-
Breast Cancer Survivorship Biorepository
RECRUITING
-
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
RECRUITING
-
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
RECRUITING · NA
-
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
RECRUITING · Phase 3
-
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.